Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular disease, immunology, oncology and diseases of the central nervous system.
For more information about Entrada, please visit www.entradatx.com .
For more information about Entrada, please visit www.entradatx.com .
Location: United States, Massachusetts, Boston
Employees: 51-200
Total raised: $175M
Founded date: 2016
Investors 6
| Date | Name | Website |
| - | Agent Capi... | agentcapit... |
| 18.05.2023 | MPM Capita... | mpmcapital... |
| - | 5AM Ventur... | 5amventure... |
| - | MRL Ventur... | mrlv.com |
| - | TCG Crosso... | tcgcrossov... |
| - | MPM BioImp... | mpmbioimpa... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 02.04.2021 | Series B | $116M | - |
| 18.12.2018 | Series A | $59M | - |
Mentions in press and media 16
| Date | Title | Description |
| 24.06.2024 | Entrada Therapeutics Announces $100 Million Registered Direct Offering | BOSTON, June 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular t... |
| 13.03.2024 | Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results | - |
| 31.03.2021 | Entrada Therapeutics Announces Closing of $116 Million Series B Financing | - |
| 31.03.2021 | Entrada Therapeutics Closes $116M Series B Financing | Entrada Therapeutics Inc., a Boston, MA-based biotechnology company dedicated to advancing treatment of devastating diseases using intracellular biologics, closed a $116m Series B financing. The round was led by Wellington Management Compan... |
| 31.03.2021 | Entrada Therapeutics Announces Closing of $116 Million Series B Financing | - |
| 31.03.2021 | Entrada Therapeutics Announces Closing of $116 Million Series B Financing | - |
| 31.03.2021 | Entrada Therapeutics Announces Closing of $116 Million Series B Financing | Entrada Therapeutics Inc., a privately-held biotechnology company dedicated to transforming the treatment of devastating diseases using intracellular biologics, today announced the successful completion of a $116 million Series B financing.... |
| 31.03.2021 | Entrada Therapeutics Closes $116M Series B | BOSTON, MA, Entrada Therapeutics announced the successful completion of a $116 million Series B financing led by Wellington Management Company. >> Click here for more funding data on Entrada Therapeutics >> To export Entrada... |
| 04.11.2019 | Entrada Therapeutics Appoints Nathan Dowden COO | Entrada Therapeutics, a biotechnology company dedicated to transforming the treatment of devastating diseases through the intracellular delivery of biologics, today announced the appointment of Nathan J. Dowden as Chief Operating Officer. M... |
| 19.12.2018 | Top startup news for today, Wednesday, December 19 | Good afternoon! Here are some of the top technology startup news stories for today, Wednesday, December 19. Startup funder Clearbanc, raises a total of $120 million in just two months. Just four weeks after announcing it had raiseda $70 mi... |
Show more